



NDA 022304/S-003
NDA 022304/S-004

SUPPLEMENT APPROVAL

Ortho-McNeil-Janssen Pharmaceuticals, Inc.
c/o Johnson & Johnson Pharmaceutical Research
& Development, L.L.C.
1125 Trenton-Harbourton Road, P.O. Box 200
Titusville, NJ 08560-0200

Attention: Kathleen F. Dusek, R.Ph., RAC
Associate Director, Regulatory Affairs

Dear Ms. Dusek:

Please refer to your Supplemental New Drug Applications dated March 10 and June 21, 2010, received March 10 and June 22, 2010, (Supplement 003 and 004, respectively) and submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nucynta (tapentadol).

These "Changes Being Effected" supplemental new drug applications provide for the addition of two post-marketing adverse events (hallucinations and headache). We also note that your submissions included the Medication Guide, which remains unchanged from our November 9, 2009, letter approving Supplement 001.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling text for the package insert and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Matt Sullivan, Regulatory Project Manager, at 301-796-1245.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, M.D.
Deputy Director
Division of Anesthesia and Analgesia Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON H HERTZ
11/01/2010